SU‐FF‐T‐504: An Integrated Software Framework for Radiotherapy Research and Outcome Analysis for Stereotactic Body Radiotherapy

D. Liu, M. Ajlouni, JianYue Jin, A. Patel, B. Movsas, S. Ryu, I. Chetty

Research output: Contribution to journalArticle

Abstract

Purpose: To develop a software framework which allows analysis and evaluation of outcomes for patients treated with hypo‐fractionated stereotactic body radiotherapy (SBRT) Method and Materials: An outcomes‐study database was designed, under IRB‐approval, to collect and analyze medical information for lung cancer patients undergoing SBRT. The outcomes‐study database incorporates a variety of patient information, including demographic, social, diagnostic, treatment and follow‐up data. A software tool with a graphical user interface was developed to calculate biological dose indices, including TCP, EUD (Niemierko) and NTCP (Lyman‐Kutcher‐Burman and relative seriality models). Biologically effective doses are determined from dose distributions and DVHs, automatically imported from the treatment planning systems. Results: Approximately 200 SBRT patients' medical records have been populated into the outcomes database. To demonstrate the functionality of the software framework, 11 lung cancer patients treated with SBRT (12 Gy/fraction × 4 fractions) for central lesions (tumors within a 2 cm zone of the proximal bronchial tree) were reviewed. The linear‐quadratic (LQ) adjusted mean lung dose was 13.38 Gy (range: 9.24 Gy to 16.50 Gy) with an α/β ratio of 3.0 Gy. Observed lung toxicities were reviewed using the database and showed the regimen to be well tolerated: none of the patients developed grades 3–5 toxicities and only 2 lower‐grade toxicities were noted. The calculated NTCP ranged from 1.73% to 8.22% using the LKB model, with parameters n=1, m=0.33, TD 50 =30.5 Gy. Conclusions: One of the goals of the outcomes database is to enable the investigation of correlation between dose, volume and effect for patients treated with SBRT, using non‐standard, hypo‐fractionated RT doses. Parameters specific to biological dose models are being updated using maximum likelihood analysis of calculated probabilities vs. observed outcomes for this large cohort of patients. Such outcomes studies are important in understanding the efficacy of new treatment paradigms.

Original languageEnglish (US)
Number of pages1
JournalMedical Physics
Volume36
Issue number6
DOIs
StatePublished - Jan 1 2009

Fingerprint

Radiosurgery
Radiotherapy
Software
Outcome Assessment (Health Care)
Databases
Lung Neoplasms
Biological Models
Lung
Medical Records
Demography
Therapeutics

ASJC Scopus subject areas

  • Biophysics
  • Radiology Nuclear Medicine and imaging

Cite this

SU‐FF‐T‐504 : An Integrated Software Framework for Radiotherapy Research and Outcome Analysis for Stereotactic Body Radiotherapy. / Liu, D.; Ajlouni, M.; Jin, JianYue; Patel, A.; Movsas, B.; Ryu, S.; Chetty, I.

In: Medical Physics, Vol. 36, No. 6, 01.01.2009.

Research output: Contribution to journalArticle

Liu, D. ; Ajlouni, M. ; Jin, JianYue ; Patel, A. ; Movsas, B. ; Ryu, S. ; Chetty, I. / SU‐FF‐T‐504 : An Integrated Software Framework for Radiotherapy Research and Outcome Analysis for Stereotactic Body Radiotherapy. In: Medical Physics. 2009 ; Vol. 36, No. 6.
@article{c150e30d97b44143afe82dd41d9f958b,
title = "SU‐FF‐T‐504: An Integrated Software Framework for Radiotherapy Research and Outcome Analysis for Stereotactic Body Radiotherapy",
abstract = "Purpose: To develop a software framework which allows analysis and evaluation of outcomes for patients treated with hypo‐fractionated stereotactic body radiotherapy (SBRT) Method and Materials: An outcomes‐study database was designed, under IRB‐approval, to collect and analyze medical information for lung cancer patients undergoing SBRT. The outcomes‐study database incorporates a variety of patient information, including demographic, social, diagnostic, treatment and follow‐up data. A software tool with a graphical user interface was developed to calculate biological dose indices, including TCP, EUD (Niemierko) and NTCP (Lyman‐Kutcher‐Burman and relative seriality models). Biologically effective doses are determined from dose distributions and DVHs, automatically imported from the treatment planning systems. Results: Approximately 200 SBRT patients' medical records have been populated into the outcomes database. To demonstrate the functionality of the software framework, 11 lung cancer patients treated with SBRT (12 Gy/fraction × 4 fractions) for central lesions (tumors within a 2 cm zone of the proximal bronchial tree) were reviewed. The linear‐quadratic (LQ) adjusted mean lung dose was 13.38 Gy (range: 9.24 Gy to 16.50 Gy) with an α/β ratio of 3.0 Gy. Observed lung toxicities were reviewed using the database and showed the regimen to be well tolerated: none of the patients developed grades 3–5 toxicities and only 2 lower‐grade toxicities were noted. The calculated NTCP ranged from 1.73{\%} to 8.22{\%} using the LKB model, with parameters n=1, m=0.33, TD 50 =30.5 Gy. Conclusions: One of the goals of the outcomes database is to enable the investigation of correlation between dose, volume and effect for patients treated with SBRT, using non‐standard, hypo‐fractionated RT doses. Parameters specific to biological dose models are being updated using maximum likelihood analysis of calculated probabilities vs. observed outcomes for this large cohort of patients. Such outcomes studies are important in understanding the efficacy of new treatment paradigms.",
author = "D. Liu and M. Ajlouni and JianYue Jin and A. Patel and B. Movsas and S. Ryu and I. Chetty",
year = "2009",
month = "1",
day = "1",
doi = "10.1118/1.3182002",
language = "English (US)",
volume = "36",
journal = "Medical Physics",
issn = "0094-2405",
publisher = "AAPM - American Association of Physicists in Medicine",
number = "6",

}

TY - JOUR

T1 - SU‐FF‐T‐504

T2 - An Integrated Software Framework for Radiotherapy Research and Outcome Analysis for Stereotactic Body Radiotherapy

AU - Liu, D.

AU - Ajlouni, M.

AU - Jin, JianYue

AU - Patel, A.

AU - Movsas, B.

AU - Ryu, S.

AU - Chetty, I.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Purpose: To develop a software framework which allows analysis and evaluation of outcomes for patients treated with hypo‐fractionated stereotactic body radiotherapy (SBRT) Method and Materials: An outcomes‐study database was designed, under IRB‐approval, to collect and analyze medical information for lung cancer patients undergoing SBRT. The outcomes‐study database incorporates a variety of patient information, including demographic, social, diagnostic, treatment and follow‐up data. A software tool with a graphical user interface was developed to calculate biological dose indices, including TCP, EUD (Niemierko) and NTCP (Lyman‐Kutcher‐Burman and relative seriality models). Biologically effective doses are determined from dose distributions and DVHs, automatically imported from the treatment planning systems. Results: Approximately 200 SBRT patients' medical records have been populated into the outcomes database. To demonstrate the functionality of the software framework, 11 lung cancer patients treated with SBRT (12 Gy/fraction × 4 fractions) for central lesions (tumors within a 2 cm zone of the proximal bronchial tree) were reviewed. The linear‐quadratic (LQ) adjusted mean lung dose was 13.38 Gy (range: 9.24 Gy to 16.50 Gy) with an α/β ratio of 3.0 Gy. Observed lung toxicities were reviewed using the database and showed the regimen to be well tolerated: none of the patients developed grades 3–5 toxicities and only 2 lower‐grade toxicities were noted. The calculated NTCP ranged from 1.73% to 8.22% using the LKB model, with parameters n=1, m=0.33, TD 50 =30.5 Gy. Conclusions: One of the goals of the outcomes database is to enable the investigation of correlation between dose, volume and effect for patients treated with SBRT, using non‐standard, hypo‐fractionated RT doses. Parameters specific to biological dose models are being updated using maximum likelihood analysis of calculated probabilities vs. observed outcomes for this large cohort of patients. Such outcomes studies are important in understanding the efficacy of new treatment paradigms.

AB - Purpose: To develop a software framework which allows analysis and evaluation of outcomes for patients treated with hypo‐fractionated stereotactic body radiotherapy (SBRT) Method and Materials: An outcomes‐study database was designed, under IRB‐approval, to collect and analyze medical information for lung cancer patients undergoing SBRT. The outcomes‐study database incorporates a variety of patient information, including demographic, social, diagnostic, treatment and follow‐up data. A software tool with a graphical user interface was developed to calculate biological dose indices, including TCP, EUD (Niemierko) and NTCP (Lyman‐Kutcher‐Burman and relative seriality models). Biologically effective doses are determined from dose distributions and DVHs, automatically imported from the treatment planning systems. Results: Approximately 200 SBRT patients' medical records have been populated into the outcomes database. To demonstrate the functionality of the software framework, 11 lung cancer patients treated with SBRT (12 Gy/fraction × 4 fractions) for central lesions (tumors within a 2 cm zone of the proximal bronchial tree) were reviewed. The linear‐quadratic (LQ) adjusted mean lung dose was 13.38 Gy (range: 9.24 Gy to 16.50 Gy) with an α/β ratio of 3.0 Gy. Observed lung toxicities were reviewed using the database and showed the regimen to be well tolerated: none of the patients developed grades 3–5 toxicities and only 2 lower‐grade toxicities were noted. The calculated NTCP ranged from 1.73% to 8.22% using the LKB model, with parameters n=1, m=0.33, TD 50 =30.5 Gy. Conclusions: One of the goals of the outcomes database is to enable the investigation of correlation between dose, volume and effect for patients treated with SBRT, using non‐standard, hypo‐fractionated RT doses. Parameters specific to biological dose models are being updated using maximum likelihood analysis of calculated probabilities vs. observed outcomes for this large cohort of patients. Such outcomes studies are important in understanding the efficacy of new treatment paradigms.

UR - http://www.scopus.com/inward/record.url?scp=85024803763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024803763&partnerID=8YFLogxK

U2 - 10.1118/1.3182002

DO - 10.1118/1.3182002

M3 - Article

AN - SCOPUS:85024803763

VL - 36

JO - Medical Physics

JF - Medical Physics

SN - 0094-2405

IS - 6

ER -